NASDAQ : TRAX
First Tracks Biotherapeutics, Inc. — Key statistics
United States
Last price 45.08 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.89B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.84B |
| Enterprise Value | 1.68B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 42.02M |
| Shares Outstanding | 42.02M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 1.56% |
| Owned by Institutions (%) | 72.26% |
| Float | 34.47M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 9.45 |
| P/TBV Ratio | 11.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 14.28 |
| Quick Ratio | 13.91 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -99.35% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 38.92 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 65.79 |
| Average Volume (20 Days) | 1,181,804 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6.96M |
| Short Previous Month | 5.19M |
| Short % of Shares Out | 16.56% |
| Short % of Float | 20.19% |
| Short Ratio (days to cover) | 6.01 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -169.58M |
| Pretax Income | -160.30M |
| Net Income | -160.30M |
| EBITDA | -169.08M |
| EBIT | -169.58M |
| Earnings Per Share (EPS) | -$4.53 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 168.02M |
| Total Debt | 4.33M |
| Net Cash | 163.69M |
| Net Cash Per Share | $3.90 |
| Equity (Book Value) | 168.80M |
| Book Value Per Share | 4.77 |
| Working Capital | 165.30M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -123.76M |
| Capital Expenditures | -55,000 |
| Depreciation & Amortization | 501,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -123.82M |
| FCF Per Share | -$2.95 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -10.33% |
| FCF Yield | -6.44% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $74.17 |
| Price Target Difference | 69.15% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |